Jorge Coronado Daza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jorge Coronado Daza has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Gerard Urrútia
Institut de Recerca Sant Pau (IR SANT PAU) - CIBERESP, Barcelona, Spain
3 shared publications Amaury Ariza García
Universidad de Cartagena Facultad de Medicina, Departamento Médico, Grupo de Investigación Alta Tensión Sede Zaragocilla, Campus de la Salud Cartagena Colombia 130015
2 shared publicationsCarol Páez-Canro
Universidad Nacional de Colombia Instituto de Investigaciones Clínicas, Facultad de Medicina Bogota Colombia
2 shared publications- Cesar Loza Munarriz
Universidad Peruana Cayetano Heredia
2 shared publications - Diana Romero Florez
Clínica San Rafael
2 shared publications - Ismael de Jesús Yepes Barreto
Universidad de Cartagena
2 shared publications
Latest Publications
- Open Access
- 30 September 2024
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 39 (3) , 358
Respuesta a la carta al editor
- 30 September 2024
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 39 (3) , 358
Open AccessRespuesta a la carta al editor
- Open Access
- 27 September 2023
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 38 (3) , 278-289
Factores de riesgo para fibrosis hepática en pacientes diabéticos con enfermedad renal cronica terminal
Introducción: la cirrosis hepática es la cuarta causa de muerte en el mundo. Actualmente, la enfermedad hepática por depósito de grasa es la causa más frecuente de hepatopatía crónica en la mayoría de los países. La identificación de factores de riesgo para la presencia de fibrosis hepática en una población con enfermedad renal crónica terminal puede facilitar el diagnóstico temprano de esta complicación y permitir la activación de protocolos de seguimiento para disminuir la morbimortalidad en estos pacientes. Metodología: se realizó un estudio de corte transversal y analítico. Se incluyeron pacientes en hemodiálisis, mayores de 18 años con diagnóstico de diabetes mellitus y de enfermedad renal crónica terminal. El contraste de hipótesis se realizó a través de la prueba de chi cuadrado y la T de Student, según correspondiera. La significación estadística se estableció con un valor p = 0,05. Resultados: se observó una prevalencia de fibrosis hepática significativa y cirrosis del 17%. Los factores asociados a la presencia de fibrosis hepática fueron los antecedentes de enfermedad cerebrovascular, la enfermedad vascular periférica, el índice de masa corporal (IMC), el colesterol total, la hemoglobina glicosilada, el sodio y el aspartato-aminotransferasa (AST). No se observó relación entre el puntaje de NAFLD (enfermedad del hígado graso no alcohólico), el índice APRI (AST to Platelet Ratio Index) y la presencia de fibrosis. Conclusión: la prevalencia de fibrosis hepática significativa en pacientes con diabetes y ERCT es similar a la reportada en otras poblaciones de pacientes con diabetes. Sin embargo, algunos factores, como el IMC, podrían comportarse de forma diferente y favorecer la aparición de lesión hepática con grados menores de obesidad a los reportados previamente en la literatura.
- 27 September 2023
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 38 (3) , 278-289
Open AccessFactores de riesgo para fibrosis hepática en pacientes diabéticos con enfermedad renal cronica terminal
Introducción: la cirrosis hepática es la cuarta causa de muerte en el mundo. Actualmente, la enfermedad hepática por depósito de grasa es la causa más frecuente de hepatopatía crónica en la mayoría de los países. La identificación de factores de riesgo para la presencia de fibrosis hepática en una población con enfermedad renal crónica terminal puede facilitar el diagnóstico temprano de esta complicación y permitir la activación de protocolos de seguimiento para disminuir la morbimortalidad en estos pacientes. Metodología: se realizó un estudio de corte transversal y analítico. Se incluyeron pacientes en hemodiálisis, mayores de 18 años con diagnóstico de diabetes mellitus y de enfermedad renal crónica terminal. El contraste de hipótesis se realizó a través de la prueba de chi cuadrado y la T de Student, según correspondiera. La significación estadística se estableció con un valor p = 0,05. Resultados: se observó una prevalencia de fibrosis hepática significativa y cirrosis del 17%. Los factores asociados a la presencia de fibrosis hepática fueron los antecedentes de enfermedad cerebrovascular, la enfermedad vascular periférica, el índice de masa corporal (IMC), el colesterol total, la hemoglobina glicosilada, el sodio y el aspartato-aminotransferasa (AST). No se observó relación entre el puntaje de NAFLD (enfermedad del hígado graso no alcohólico), el índice APRI (AST to Platelet Ratio Index) y la presencia de fibrosis. Conclusión: la prevalencia de fibrosis hepática significativa en pacientes con diabetes y ERCT es similar a la reportada en otras poblaciones de pacientes con diabetes. Sin embargo, algunos factores, como el IMC, podrían comportarse de forma diferente y favorecer la aparición de lesión hepática con grados menores de obesidad a los reportados previamente en la literatura.
- Open Access
- 29 June 2022
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 9 (2)
Anosmia como manifestación inicial de COVID-19 en pacientes de hemodiálisis
Contexto. Los pacientes en hemodiálisis son una población susceptible para la enfermedad causada por el SARS-CoV-2, enfermedad por el coronavirus 2019 (COVID-19), siendo el diagnóstico temprano una necesidad urgente por considerarse una población de riesgo por presentar cuadros severos y graves. Objetivo. Estimar si la anosmia de inicio súbito permite una detección temprana de la infección por COVID-19, en pacientes de hemodiálisis sin síntomas clásicos (que no presentaron malestar general, síntomas respiratorios o gastrointestinales al inicio de la enfermedad). Metodología. Se realizó un estudio de prueba diagnóstica durante los meses de septiembre y octubre del 2020 en tres unidades de hemodiálisis en Colombia. Fueron incluidos pacientes adultos, sin síntomas clásicos para COVID-19. Se excluyó a los pacientes con infección previa por COVID-19 o con antecedentes de alteración del olfato. Se recolectaron datos demográficos, clínicos y de laboratorio, previa firma de consentimiento informado avalado por el comité de ética (CEI-487). La anosmia se exploró con una prueba subjetiva para detección de olores antes del inicio de la hemodiálisis. Resultados. Se incluyeron 587 pacientes. La prevalencia de anosmia fue de 0,85?% (cinco pacientes) y una incidencia de COVID-19 de 1,19?% (siete pacientes). No hubo diferencia estadística al comparar las variables demográficas, clínicas y de laboratorio entre pacientes con y sin anosmia. La presencia de anosmia tuvo una sensibilidad y un valor predictivo positivo del 0?%, pero una especificidad del 99,14?% y un valor predictivo negativo del 98,8?%. La exactitud fue del 97,9?%. Conclusiones. La prevalencia de anosmia en nuestra población de hemodiálisis fue baja. Se debería indagar en el triaje cualquier síntoma (incluida la alteración del sentido del olfato) como estrategia para detectar de forma temprana casos individuales de COVID-19 o un brote en las unidades de hemodiálisis. Métodos: se realizó un estudio de prueba diagnóstica en tres unidades de hemodiálisis en Colombia. Fueron incluidos pacientes adultos, sin síntomas clásicos para COVID-19. Se excluyeron pacientes con infección previa por COVID-19 o con antecedentes de alteración del olfato. Se recolectaron datos demográficos, clínicos y de laboratorio. La anosmia se exploró con una prueba objetiva para detección de olores antes del inicio de la hemodiálisis. Resultados: se incluyeron 587 pacientes. La prevalencia de anosmia fue de 0.85% (5 pacientes) y una incidencia de COVID-19 de 1.19% (7 pacientes). No hubo diferencia estadística al comparar las variables demográficas, clínicas y de laboratorio entre pacientes con y sin anosmia. La presencia de anosmia tuvo una sensibilidad y un valor predictivo positivo del 0%, pero una especificidad del 99.14% y un valor predictivo negativo del 98.8%. La exactitud fue del 97.9%. Conclusiones: la prevalencia de anosmia en la población de hemodiálisis es baja. Se debe indagar en el TRIAGE cualquier síntoma como estrategia para detectar de forma temprana casos individuales de COVID-19 o un brote en las Unidades Renales. Palabras claves: enfermedad renal crónica, hemodiálisis, anosmia, COVID-19, prevalencia, pandemia.
- 29 June 2022
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 9 (2)
Open AccessAnosmia como manifestación inicial de COVID-19 en pacientes de hemodiálisis
Contexto. Los pacientes en hemodiálisis son una población susceptible para la enfermedad causada por el SARS-CoV-2, enfermedad por el coronavirus 2019 (COVID-19), siendo el diagnóstico temprano una necesidad urgente por considerarse una población de riesgo por presentar cuadros severos y graves. Objetivo. Estimar si la anosmia de inicio súbito permite una detección temprana de la infección por COVID-19, en pacientes de hemodiálisis sin síntomas clásicos (que no presentaron malestar general, síntomas respiratorios o gastrointestinales al inicio de la enfermedad). Metodología. Se realizó un estudio de prueba diagnóstica durante los meses de septiembre y octubre del 2020 en tres unidades de hemodiálisis en Colombia. Fueron incluidos pacientes adultos, sin síntomas clásicos para COVID-19. Se excluyó a los pacientes con infección previa por COVID-19 o con antecedentes de alteración del olfato. Se recolectaron datos demográficos, clínicos y de laboratorio, previa firma de consentimiento informado avalado por el comité de ética (CEI-487). La anosmia se exploró con una prueba subjetiva para detección de olores antes del inicio de la hemodiálisis. Resultados. Se incluyeron 587 pacientes. La prevalencia de anosmia fue de 0,85?% (cinco pacientes) y una incidencia de COVID-19 de 1,19?% (siete pacientes). No hubo diferencia estadística al comparar las variables demográficas, clínicas y de laboratorio entre pacientes con y sin anosmia. La presencia de anosmia tuvo una sensibilidad y un valor predictivo positivo del 0?%, pero una especificidad del 99,14?% y un valor predictivo negativo del 98,8?%. La exactitud fue del 97,9?%. Conclusiones. La prevalencia de anosmia en nuestra población de hemodiálisis fue baja. Se debería indagar en el triaje cualquier síntoma (incluida la alteración del sentido del olfato) como estrategia para detectar de forma temprana casos individuales de COVID-19 o un brote en las unidades de hemodiálisis. Métodos: se realizó un estudio de prueba diagnóstica en tres unidades de hemodiálisis en Colombia. Fueron incluidos pacientes adultos, sin síntomas clásicos para COVID-19. Se excluyeron pacientes con infección previa por COVID-19 o con antecedentes de alteración del olfato. Se recolectaron datos demográficos, clínicos y de laboratorio. La anosmia se exploró con una prueba objetiva para detección de olores antes del inicio de la hemodiálisis. Resultados: se incluyeron 587 pacientes. La prevalencia de anosmia fue de 0.85% (5 pacientes) y una incidencia de COVID-19 de 1.19% (7 pacientes). No hubo diferencia estadística al comparar las variables demográficas, clínicas y de laboratorio entre pacientes con y sin anosmia. La presencia de anosmia tuvo una sensibilidad y un valor predictivo positivo del 0%, pero una especificidad del 99.14% y un valor predictivo negativo del 98.8%. La exactitud fue del 97.9%. Conclusiones: la prevalencia de anosmia en la población de hemodiálisis es baja. Se debe indagar en el TRIAGE cualquier síntoma como estrategia para detectar de forma temprana casos individuales de COVID-19 o un brote en las Unidades Renales. Palabras claves: enfermedad renal crónica, hemodiálisis, anosmia, COVID-19, prevalencia, pandemia.
- Open Access
- 13 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0266202
Recommendations of high-quality clinical practice guidelines related to the process of starting dialysis: A systematic review
Background: The optimal time for initiation of dialysis and which modality to choose as the starting therapy is currently unclear. This systematic review aimed to assess the recommendations across high-quality clinical practice guidelines (CPGs) related to the start of dialysis. Methods: We systematically searched MEDLINE, EMBASE, Web of Science, LILACS, and databases of organisations that develop CPGs between September 2008 to August 2021 for CPGs that addressed recommendations on the timing of initiation of dialysis, selection of dialysis modality, and interventions to support the decision-making process to select a dialysis modality. We used the Appraisal of Guidelines for Research and Evaluation instrument to assess the methodological quality of the CPGs and included only high-quality CPGs. This study is registered in PROSPERO, number CRD42018110325. Results: We included 12 high-quality CPGs. Six CPGs addressed recommendations related to the timing of initiating dialysis, and all agreed on starting dialysis in the presence of symptoms or signs. Six CPGs addressed recommendations related to the selection of modality but varied greatly in their content. Nine CPGs addressed recommendations related to interventions to support the decision-making process. Eight CPGs agreed on recommended educational programs that include information about dialysis options. One CPG considered using patient decision aids a strong recommendation. Limitations: We could have missed potentially relevant guidelines since we limited our search to CPGs published from 2008, and we set up a cut-off point of 60% in domains of the rigour of development and editorial independence. Conclusion: High-quality CPGs related to the process of starting dialysis were consistent in initiating dialysis in the presence of symptoms or signs and offering patients education at the point of decision-making. There was variability in how CPGs addressed the issue of dialysis modality selection. CPGs should improve strategies on putting recommendations into practice and the quality of evidence to aid decision-making for patients. Registration: The protocol of this systematic review has been registered in the international prospective register of systematic reviews (PROSPERO) under the registration number: CRD CRD42018110325. https://clinicaltrials.gov/ct2/show/CRD42018110325.
- 13 June 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0266202
Open AccessRecommendations of high-quality clinical practice guidelines related to the process of starting dialysis: A systematic review
Background: The optimal time for initiation of dialysis and which modality to choose as the starting therapy is currently unclear. This systematic review aimed to assess the recommendations across high-quality clinical practice guidelines (CPGs) related to the start of dialysis. Methods: We systematically searched MEDLINE, EMBASE, Web of Science, LILACS, and databases of organisations that develop CPGs between September 2008 to August 2021 for CPGs that addressed recommendations on the timing of initiation of dialysis, selection of dialysis modality, and interventions to support the decision-making process to select a dialysis modality. We used the Appraisal of Guidelines for Research and Evaluation instrument to assess the methodological quality of the CPGs and included only high-quality CPGs. This study is registered in PROSPERO, number CRD42018110325. Results: We included 12 high-quality CPGs. Six CPGs addressed recommendations related to the timing of initiating dialysis, and all agreed on starting dialysis in the presence of symptoms or signs. Six CPGs addressed recommendations related to the selection of modality but varied greatly in their content. Nine CPGs addressed recommendations related to interventions to support the decision-making process. Eight CPGs agreed on recommended educational programs that include information about dialysis options. One CPG considered using patient decision aids a strong recommendation. Limitations: We could have missed potentially relevant guidelines since we limited our search to CPGs published from 2008, and we set up a cut-off point of 60% in domains of the rigour of development and editorial independence. Conclusion: High-quality CPGs related to the process of starting dialysis were consistent in initiating dialysis in the presence of symptoms or signs and offering patients education at the point of decision-making. There was variability in how CPGs addressed the issue of dialysis modality selection. CPGs should improve strategies on putting recommendations into practice and the quality of evidence to aid decision-making for patients. Registration: The protocol of this systematic review has been registered in the international prospective register of systematic reviews (PROSPERO) under the registration number: CRD CRD42018110325. https://clinicaltrials.gov/ct2/show/CRD42018110325.
- Open Access
- 16 February 2021
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (2) , e525
Consenso colombiano de expertos sobre recomendaciones informadas en la evidencia para el manejo de la infección por SARS-CoV-2/COVID-19 en adulto mayor multimorbido con enfermedad renal crónica
Introducción: La infección por SARS-CoV-2 es una pandemia con importante impacto en población adulta mayor con múltiples morbilidades. Objetivo: Desarrollar mediante un consenso de expertos, recomendaciones informadas en evidencia para la prevención, diagnóstico y manejo de infección por SARS CoV2/COVID-19 en paciente adulto mayor multimorbido con enfermedad renal crónica. Metodología: A partir de la evidencia recolectada a través de una revisión de literatura en Pubmed, Embase y sociedades científicas, se formularon recomendaciones que fueron sometidas a la consulta de expertos en nefrología, geriatría y cuidados paliativos. La calidad de evidencia se evalúo con herramientas en función del tipo de documento. Las recomendaciones aprobadas fueron clasificadas de acuerdo a su dirección y fuerza. Resultados: Veintidós expertos declararon su conflicto de interés y diligenciaron la herramienta de consulta entre el 02 y 10 de agosto de 2020. El porcentaje de acuerdo por cada recomendación oscilo entre el 90.9 y 100%. Se presentan 32 recomendaciones para el manejo de la infección por SARS-CoV-2 en paciente adulto mayor multimorbido con enfermedad renal crónica. Conclusión: Las recomendaciones formuladas orientan la toma de decisiones de los profesionales de la salud involucrados en la atención de pacientes mayores con enfermedad renal crónica y otras morbilidades que presentan infección por SARS-CoV-2.
- 16 February 2021
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 8 (2) , e525
Open AccessConsenso colombiano de expertos sobre recomendaciones informadas en la evidencia para el manejo de la infección por SARS-CoV-2/COVID-19 en adulto mayor multimorbido con enfermedad renal crónica
Introducción: La infección por SARS-CoV-2 es una pandemia con importante impacto en población adulta mayor con múltiples morbilidades. Objetivo: Desarrollar mediante un consenso de expertos, recomendaciones informadas en evidencia para la prevención, diagnóstico y manejo de infección por SARS CoV2/COVID-19 en paciente adulto mayor multimorbido con enfermedad renal crónica. Metodología: A partir de la evidencia recolectada a través de una revisión de literatura en Pubmed, Embase y sociedades científicas, se formularon recomendaciones que fueron sometidas a la consulta de expertos en nefrología, geriatría y cuidados paliativos. La calidad de evidencia se evalúo con herramientas en función del tipo de documento. Las recomendaciones aprobadas fueron clasificadas de acuerdo a su dirección y fuerza. Resultados: Veintidós expertos declararon su conflicto de interés y diligenciaron la herramienta de consulta entre el 02 y 10 de agosto de 2020. El porcentaje de acuerdo por cada recomendación oscilo entre el 90.9 y 100%. Se presentan 32 recomendaciones para el manejo de la infección por SARS-CoV-2 en paciente adulto mayor multimorbido con enfermedad renal crónica. Conclusión: Las recomendaciones formuladas orientan la toma de decisiones de los profesionales de la salud involucrados en la atención de pacientes mayores con enfermedad renal crónica y otras morbilidades que presentan infección por SARS-CoV-2.
- Open Access
- 28 May 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 192
Quality assessment of clinical practice guidelines for chronic kidney disease: a systematic review
Chronic kidney disease (CKD) is a worldwide public health problem. Clinical practice guidelines (CPGs) are being developed and implemented in order to improve clinical practice related to the detection and treatment of CKD. The objective of our study was to evaluate the quality of CPGs regarding the CKD and to examine whether there are factors which influence their quality. A systematic search was conducted to identify all CPGs regarding the early diagnosis and treatment of CKD. The CPGs quality were evaluated by three reviewers using the AGREE II instrument to decide if the guidelines are recommended for their use in clinical practice. In total, 13 CPGs were identified: five from America, six from Europe, one from Asia, and one from Oceania. Five CPGs were recommended for their use in clinical practice; since all their domains achieved the medium or high category. Furthermore, six CPGs were recommended with modifications, as the stakeholders’ involvement, applicability, and editorial independence domains were evaluated as low category. These domains, as well as the rigor of the development domain, reached the very low category in those CPGs that were not recommended for its use in clinical practice. In all CPGs, the domains with the lowest average were the stakeholder involvement and the applicability. When comparing the domains of the CPGs according to the origin, type of developer group, the checklist used during the development and the publication period, a significantly higher average in the domain stakeholder involvement was found in the CPGs from Asia and Oceania compared to the ones in Latin America. Additionally, a significantly higher average in the applicability domain was found in the CPGs developed by CPGs developer organizations compared to those developed by medical societies. In total, 85% of the CPGs regarding CKD were recommended or recommended with modifications. The stakeholder involvement and applicability domains are assessed in the low category, which might affect the CPGs implementation. In order to save resources in low- and middle-income countries, an adaptation of the recommended CPGs should be considered.
- 28 May 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 192
Open AccessQuality assessment of clinical practice guidelines for chronic kidney disease: a systematic review
Chronic kidney disease (CKD) is a worldwide public health problem. Clinical practice guidelines (CPGs) are being developed and implemented in order to improve clinical practice related to the detection and treatment of CKD. The objective of our study was to evaluate the quality of CPGs regarding the CKD and to examine whether there are factors which influence their quality. A systematic search was conducted to identify all CPGs regarding the early diagnosis and treatment of CKD. The CPGs quality were evaluated by three reviewers using the AGREE II instrument to decide if the guidelines are recommended for their use in clinical practice. In total, 13 CPGs were identified: five from America, six from Europe, one from Asia, and one from Oceania. Five CPGs were recommended for their use in clinical practice; since all their domains achieved the medium or high category. Furthermore, six CPGs were recommended with modifications, as the stakeholders’ involvement, applicability, and editorial independence domains were evaluated as low category. These domains, as well as the rigor of the development domain, reached the very low category in those CPGs that were not recommended for its use in clinical practice. In all CPGs, the domains with the lowest average were the stakeholder involvement and the applicability. When comparing the domains of the CPGs according to the origin, type of developer group, the checklist used during the development and the publication period, a significantly higher average in the domain stakeholder involvement was found in the CPGs from Asia and Oceania compared to the ones in Latin America. Additionally, a significantly higher average in the applicability domain was found in the CPGs developed by CPGs developer organizations compared to those developed by medical societies. In total, 85% of the CPGs regarding CKD were recommended or recommended with modifications. The stakeholder involvement and applicability domains are assessed in the low category, which might affect the CPGs implementation. In order to save resources in low- and middle-income countries, an adaptation of the recommended CPGs should be considered.
- Open Access
- 1 January 2019
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 29 (3) , 160-165
Gender differences in dose of erythropoietin to maintain hemoglobin target in hemodialysis patients
Dialysis patients receiving erythropoietin (EPO) for anemia management are a challenge due to the significant interindividual variability in erythropoietic response. Our objective was to determine if there is a gender-dependent difference in the EPO doses required to maintain the hemoglobin (Hb) targets in adult patients undergoing hemodialysis. We conducted a historic cohort study with a 12-month follow-up. We include patients with the Hb target, normal serum albumin, and normal transferrin saturation index. Monthly data were gathered for the following: Hb level, EPO doses, and intravenous iron doses. In the 11 hemodialysis facilities included, 1844 patients were on hemodialysis. We considered 389 patients for follow-up, 190 of which were excluded mainly for failing to keep the Hb level in the established range. The final cohort for analysis included 141 men (70.9%) and 58 women (29.1%). At baseline, men weighed more than women (P < 0.001). At the end of the follow-up period, the EPO required to maintain Hb level between 10 and 13 g/dl was significantly higher in women in the monthly dose, weekly dose, and weekly EPO dose/patient weight, with no difference in the monthly iron dose. There was a significant association between female gender and the use of high EPO doses (odds ratio, 4.1; 95% confidence interval, 1.4–12.2; P = 0.01). Our study demonstrates that women require higher doses of EPO to achieve Hb targets.
- 1 January 2019
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 29 (3) , 160-165
Open AccessGender differences in dose of erythropoietin to maintain hemoglobin target in hemodialysis patients
Dialysis patients receiving erythropoietin (EPO) for anemia management are a challenge due to the significant interindividual variability in erythropoietic response. Our objective was to determine if there is a gender-dependent difference in the EPO doses required to maintain the hemoglobin (Hb) targets in adult patients undergoing hemodialysis. We conducted a historic cohort study with a 12-month follow-up. We include patients with the Hb target, normal serum albumin, and normal transferrin saturation index. Monthly data were gathered for the following: Hb level, EPO doses, and intravenous iron doses. In the 11 hemodialysis facilities included, 1844 patients were on hemodialysis. We considered 389 patients for follow-up, 190 of which were excluded mainly for failing to keep the Hb level in the established range. The final cohort for analysis included 141 men (70.9%) and 58 women (29.1%). At baseline, men weighed more than women (P < 0.001). At the end of the follow-up period, the EPO required to maintain Hb level between 10 and 13 g/dl was significantly higher in women in the monthly dose, weekly dose, and weekly EPO dose/patient weight, with no difference in the monthly iron dose. There was a significant association between female gender and the use of high EPO doses (odds ratio, 4.1; 95% confidence interval, 1.4–12.2; P = 0.01). Our study demonstrates that women require higher doses of EPO to achieve Hb targets.
- 16 December 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (6) , CD011122
Early versus delayed erythropoietin for the anaemia of end-stage kidney disease
Background Anaemia is a common complication in people with chronic kidney disease (CKD) and mainly develops as a consequence of relative erythropoietin (EPO) deficiency. Anaemia develops early in the course of disease and peaks among people with end-stage kidney disease (ESKD). Many types of EPO - also called erythropoiesis-stimulating agents (ESAs) - are used to treat anaemia in people with ESKD. ESAs have changed treatment of severe anaemia among people with CKD by relieving symptoms and avoiding complications associated with blood transfusion. However, no benefits have been found in relation to mortality rates and non-cardiac fatal events, except quality of life. Moreover, a relationship between ESA use and increased cardiovascular morbidity and mortality in patients with CKD has been reported in studies with fully correcting anaemia comparing with partial anaemia correction. Until 2012, guidelines recommended commencing ESA treatment when haemoglobin was less than 11 g/dL; the current recommendation is EPO commencement when haemoglobin is between 9 and 10 g/dL. However, advantages in commencing therapy when haemoglobin levels are greater than 10 g/dL but less than 11 g/dL remain unknown, especially among older people whose life expectancy is limited, but in whom EPO therapy may improve quality of life. Objectives To assess the clinical benefits and harms of early versus delayed EPO for anaemia in patients with ESKD undergoing haemodialysis or peritoneal dialysis Search methods We searched the Cochrane Kidney and Transplant Specialised Register to 8 July 2015 through contact with the Trials' Search Coordinator using search terms relevant to this review. Selection criteria We planned to include randomised controlled trials (RCTs) and quasi-RCTs evaluating at the clinical benefits and harms of early versus delayed EPO for anaemia in patients with ESKD undergoing haemodialysis or peritoneal dialysis. Studies comparing EPO with another EPO, placebo or no treatment were eligible for inclusion. Data collection and analysis It was planned that two authors would independently extract data from included studies and assess risk of bias using the Cochrane risk of bias tool. For dichotomous outcomes (all-causemortality, cardiovascular mortality, overall myocardial infarction, overall stroke, vascular access thrombosis, adverse effects of treatment, transfusion), we planned to use the risk ratio (RR) with 95% confidence intervals (CI). We planned to calculate the mean difference (MD) and CI 95% for continuous data (haemoglobin level) and the standardised mean difference (SMD) with CI 95% for quality of life if different scales had been used. Main results Literature searches yielded 1910 records, of these 1534 were screened after duplicates removed, of which 1376 were excluded following title and abstract assessment. We assessed 158 full text records and identified 18 studies (66 records) that were potentially eligible for inclusion. However, none matched our inclusion criteria and were excluded. Authors' conclusions We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD.
- 16 December 2015
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (6) , CD011122
Early versus delayed erythropoietin for the anaemia of end-stage kidney disease
Background Anaemia is a common complication in people with chronic kidney disease (CKD) and mainly develops as a consequence of relative erythropoietin (EPO) deficiency. Anaemia develops early in the course of disease and peaks among people with end-stage kidney disease (ESKD). Many types of EPO - also called erythropoiesis-stimulating agents (ESAs) - are used to treat anaemia in people with ESKD. ESAs have changed treatment of severe anaemia among people with CKD by relieving symptoms and avoiding complications associated with blood transfusion. However, no benefits have been found in relation to mortality rates and non-cardiac fatal events, except quality of life. Moreover, a relationship between ESA use and increased cardiovascular morbidity and mortality in patients with CKD has been reported in studies with fully correcting anaemia comparing with partial anaemia correction. Until 2012, guidelines recommended commencing ESA treatment when haemoglobin was less than 11 g/dL; the current recommendation is EPO commencement when haemoglobin is between 9 and 10 g/dL. However, advantages in commencing therapy when haemoglobin levels are greater than 10 g/dL but less than 11 g/dL remain unknown, especially among older people whose life expectancy is limited, but in whom EPO therapy may improve quality of life. Objectives To assess the clinical benefits and harms of early versus delayed EPO for anaemia in patients with ESKD undergoing haemodialysis or peritoneal dialysis Search methods We searched the Cochrane Kidney and Transplant Specialised Register to 8 July 2015 through contact with the Trials' Search Coordinator using search terms relevant to this review. Selection criteria We planned to include randomised controlled trials (RCTs) and quasi-RCTs evaluating at the clinical benefits and harms of early versus delayed EPO for anaemia in patients with ESKD undergoing haemodialysis or peritoneal dialysis. Studies comparing EPO with another EPO, placebo or no treatment were eligible for inclusion. Data collection and analysis It was planned that two authors would independently extract data from included studies and assess risk of bias using the Cochrane risk of bias tool. For dichotomous outcomes (all-causemortality, cardiovascular mortality, overall myocardial infarction, overall stroke, vascular access thrombosis, adverse effects of treatment, transfusion), we planned to use the risk ratio (RR) with 95% confidence intervals (CI). We planned to calculate the mean difference (MD) and CI 95% for continuous data (haemoglobin level) and the standardised mean difference (SMD) with CI 95% for quality of life if different scales had been used. Main results Literature searches yielded 1910 records, of these 1534 were screened after duplicates removed, of which 1376 were excluded following title and abstract assessment. We assessed 158 full text records and identified 18 studies (66 records) that were potentially eligible for inclusion. However, none matched our inclusion criteria and were excluded. Authors' conclusions We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD.
- 20 May 2014
- Published by Wiley
- No. 5
Early versus delayed erythropoietin for the anaemia of end-stage kidney disease
- 20 May 2014
- Published by Wiley
- No. 5
Early versus delayed erythropoietin for the anaemia of end-stage kidney disease